Abstract:Background: The DTaP-IPV/Hib combination vaccine can replace the acellular tetanus vaccine, polio vaccine, and the Haemophilus influenzae type B vaccine. Data on the safety of DTaP-IPV/Hib vaccines are required. We aimed to evaluate the safety of the vaccination program. Methods: Using the National Adverse Events Following Immunization (AEFI) surveillance system (CNAEFIS) in Guangzhou, China, a retrospective study was performed from May 11, 2011, to December 31, 2017. There were 376 cases of adverse events after vaccination with the DTaP IPV/Hib vaccine. The primary analysis indicators were the number of vaccines used, the number of AEFI reports received, and the reporting rate (per 100,000). Results: From May 1, 2011, to December 31, 2017, 516,000 doses of vaccine were inoculated, and 376 cases of adverse reactions were reported; the reporting rate was 72.8 per 100,000 vaccines. There were eight cases of serious AEFIs (1.5 per 100,000), with four cases of thrombocytopenic purpura (0.8 per 100,000); three cases of cyanosis of the lips, stiffness, and flexion of limbs, and convulsions (0.6 per 100,000); and one case of a high fever (0.2 per 100,000). The highest incidence of AEFIs occurred after the fourth dose (n = 207, 55.0%, 40.1 per 100,000), followed by the first dose (n = 81, 21.5%, 15.7 per 100,000), second dose (n = 48, 12.8%, 9.3 per 100,000) and third dose (n = 40, 10.6%, 7.7 per 100,000). The AEFI incidence was higher after injection of the vaccine into the deltoid muscle of the upper arm (n = 276, 73.4%, 53.5 per 100,000) than after injection of the vaccine into the thigh (n = 100, 26.6%, 19.4 per 100,000). There was a significant difference between AEFIs after injection into the deltoid of the upper arm deltoid and the thigh (x2 = 164.8, P < 0.05). Conclusions: Most of the reported AEFIs after DTaP-IPV/Hib vaccination are not serious. There were four cases of TP in this study; vaccination may be a rare cause of thrombocytopenic purpura.

Safety of influenza A(H1N1)vaccine(Split,Inactivated)

Evaluation of the Adverse Effects of Influenza Virus A(H1N1) Split Vaccine in Children and Adolescents in Shanghai

Investigation on Safety of Influenza A H1N1 Split Virus Influenza Vaccine Vaccination During the Epidemic of Pandemic Influenza A in Shanghai,2009

Adverse Events Following Immunization of H1N1 Vaccine in 160 Children

Analysis of Immunogenicity and Safety of Inactivated Split Influenza A (H1N1) Vaccine in 148 Medical Staff

Influenza A H1N1 vaccine safety:investigation of 898 vaccinated medical professionals

Post-Marketing Surveillance of Adverse Events Following Immunization with Haemophilus Influenzae Type b Conjugate Vaccine - China, 2010-2021

Surveillance and analysis on the suspected adverse events following immunization in Haidian District, Beijing City in 2012

Analysis on surveillance of rare vaccine reaction following immunization in Haidian district of Beijing ,2009-2013

Analysis on surveillance of adverse effects following immunization in Jiangxi from 2005 to 2010

Analysis on the Adverse Events Following Immunization after Measles Vaccine Supplementary Immunization Activity in Anhui Province in 2009

STUDY ON THE ADVERSE EVENTS FOLLOWING IMMUNIZATION AFTER THE MEASLES VACCINE FOLLOW-UP IMMUNIZATION IN JIANGXI PROVINCE

Surveillance for adverse events following immunization in Hebei Province, China, 2018-2020

Analysis on 124 Cases Of(suspected)adverse Events Following Immunization of Hepatitis B Vaccine Reported in Documents

The characteristics and trend of adverse events following immunization reported by information system in Jiangsu province, China, 2015–2018

Surveillance on the adverse events following immunization with the pentavalent vaccine in Zhejiang, China

Safety, Tolerability, and Immunogenicity of aH5N1 Vaccine in Adults with and without Underlying Medical Conditions

Safety of pentavalent DTaP-IPV/Hib combination vaccine in post-marketing surveillance in Guangzhou, China, from 2011 to 2017

Immunogenicity and safety of the quadrivalent inactivated split-virion influenza vaccine in populations aged ≥ 3 years: A phase 3, randomized, double-blind, non-inferiority clinical trial

Evaluation of Influenza A(H1N1) Vaccination Effectiveness in Shanghai,2009

Surveillance of adverse events following varicella vaccine immunization in Jiangsu province, China from 2017 to 2023